Titre : Méningite carcinomateuse

Méningite carcinomateuse : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement Factor I
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Méningite carcinomateuse : Questions médicales les plus fréquentes", "headline": "Méningite carcinomateuse : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Méningite carcinomateuse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-18", "dateModified": "2025-03-13", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Méningite carcinomateuse" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Tumeurs des méninges", "url": "https://questionsmedicales.fr/mesh/D008577", "about": { "@type": "MedicalCondition", "name": "Tumeurs des méninges", "code": { "@type": "MedicalCode", "code": "D008577", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.551.240.500" } } }, "about": { "@type": "MedicalCondition", "name": "Méningite carcinomateuse", "alternateName": "Meningeal Carcinomatosis", "code": { "@type": "MedicalCode", "code": "D055756", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Lidong Jiao", "url": "https://questionsmedicales.fr/author/Lidong%20Jiao", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, People's Republic of China." } }, { "@type": "Person", "name": "Yue Zhao", "url": "https://questionsmedicales.fr/author/Yue%20Zhao", "affiliation": { "@type": "Organization", "name": "Department of Neurology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China." } }, { "@type": "Person", "name": "Hui Bu", "url": "https://questionsmedicales.fr/author/Hui%20Bu", "affiliation": { "@type": "Organization", "name": "Department of Neurology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China." } }, { "@type": "Person", "name": "Koki Nakashima", "url": "https://questionsmedicales.fr/author/Koki%20Nakashima", "affiliation": { "@type": "Organization", "name": "Depertment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, 2-4-1, Tsukimi, Fukui-shi, Fukui-ken, Japan." } }, { "@type": "Person", "name": "Yoshiki Demura", "url": "https://questionsmedicales.fr/author/Yoshiki%20Demura", "affiliation": { "@type": "Organization", "name": "Depertment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, 2-4-1, Tsukimi, Fukui-shi, Fukui-ken, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A novel method for real-time analysis of the complement C3b:FH:FI complex reveals dominant negative", "datePublished": "2022-12-28", "url": "https://questionsmedicales.fr/article/36643920", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2022.1028760" } }, { "@type": "ScholarlyArticle", "name": "CNS Inflammation as the First Sign of Complement Factor I Deficiency.", "datePublished": "2023-12-22", "url": "https://questionsmedicales.fr/article/38134378", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1212/NXI.0000000000200191" } }, { "@type": "ScholarlyArticle", "name": "Hot Spot of Complement Factor I Rare Variant p.Ile357Met in Patients With Hemolytic Uremic Syndrome.", "datePublished": "2024-02-27", "url": "https://questionsmedicales.fr/article/38423159", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1053/j.ajkd.2023.12.021" } }, { "@type": "ScholarlyArticle", "name": "Model-based interspecies scaling for predicting human pharmacokinetics of CB 4332, a complement factor I protein.", "datePublished": "2024-06-28", "url": "https://questionsmedicales.fr/article/38945365", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.xphs.2024.06.022" } }, { "@type": "ScholarlyArticle", "name": "Comprehensive functional characterization of Complement factor I rare variant genotypes identified in the SCOPE Geographic Atrophy cohort.", "datePublished": "2024-06-07", "url": "https://questionsmedicales.fr/article/38852887", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jbc.2024.107452" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système nerveux", "item": "https://questionsmedicales.fr/mesh/D009422" }, { "@type": "ListItem", "position": 3, "name": "Tumeurs du système nerveux", "item": "https://questionsmedicales.fr/mesh/D009423" }, { "@type": "ListItem", "position": 4, "name": "Tumeurs du système nerveux central", "item": "https://questionsmedicales.fr/mesh/D016543" }, { "@type": "ListItem", "position": 5, "name": "Tumeurs des méninges", "item": "https://questionsmedicales.fr/mesh/D008577" }, { "@type": "ListItem", "position": 6, "name": "Méningite carcinomateuse", "item": "https://questionsmedicales.fr/mesh/D055756" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Méningite carcinomateuse - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Méningite carcinomateuse", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Méningite carcinomateuse", "description": "Comment diagnostiquer la méningite carcinomateuse ?\nQuels examens d'imagerie sont utilisés ?\nQuels marqueurs tumoraux sont recherchés ?\nQuels symptômes indiquent une méningite carcinomateuse ?\nQuelle est l'importance de l'historique médical ?", "url": "https://questionsmedicales.fr/mesh/D055756?mesh_terms=Complement+Factor+I&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Méningite carcinomateuse", "description": "Quels sont les symptômes courants ?\nY a-t-il des signes neurologiques spécifiques ?\nComment se manifeste la douleur ?\nLes symptômes varient-ils selon le type de cancer ?\nPeut-on avoir de la fièvre ?", "url": "https://questionsmedicales.fr/mesh/D055756?mesh_terms=Complement+Factor+I&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Méningite carcinomateuse", "description": "Peut-on prévenir la méningite carcinomateuse ?\nComment réduire le risque de cancer ?\nLes vaccinations aident-elles ?\nQuel rôle joue le dépistage ?\nLes facteurs environnementaux influencent-ils ?", "url": "https://questionsmedicales.fr/mesh/D055756?mesh_terms=Complement+Factor+I&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Méningite carcinomateuse", "description": "Quel est le traitement principal ?\nDes corticostéroïdes sont-ils utilisés ?\nComment gérer la douleur ?\nY a-t-il des traitements expérimentaux ?\nQuel suivi est nécessaire après traitement ?", "url": "https://questionsmedicales.fr/mesh/D055756?mesh_terms=Complement+Factor+I&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Méningite carcinomateuse", "description": "Quelles sont les complications possibles ?\nLa méningite carcinomateuse peut-elle être fatale ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il un risque de récidive ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D055756?mesh_terms=Complement+Factor+I&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Méningite carcinomateuse", "description": "Quels cancers sont associés à la méningite carcinomateuse ?\nL'âge influence-t-il le risque ?\nLe sexe joue-t-il un rôle ?\nLes antécédents familiaux sont-ils un facteur ?\nLes traitements antérieurs augmentent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D055756?mesh_terms=Complement+Factor+I&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer la méningite carcinomateuse ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic est établi par une ponction lombaire et l'analyse du liquide céphalorachidien." } }, { "@type": "Question", "name": "Quels examens d'imagerie sont utilisés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'IRM et le scanner peuvent aider à visualiser les anomalies cérébrales associées." } }, { "@type": "Question", "name": "Quels marqueurs tumoraux sont recherchés ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs comme le CA 15-3 ou le CA 19-9 peuvent être évalués dans le LCR." } }, { "@type": "Question", "name": "Quels symptômes indiquent une méningite carcinomateuse ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des maux de tête, des nausées, et des troubles neurologiques peuvent alerter." } }, { "@type": "Question", "name": "Quelle est l'importance de l'historique médical ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un antécédent de cancer est crucial pour orienter le diagnostic vers une méningite carcinomateuse." } }, { "@type": "Question", "name": "Quels sont les symptômes courants ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des maux de tête, des nausées, et des troubles de la conscience." } }, { "@type": "Question", "name": "Y a-t-il des signes neurologiques spécifiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des signes comme la confusion, la faiblesse musculaire ou des convulsions peuvent survenir." } }, { "@type": "Question", "name": "Comment se manifeste la douleur ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La douleur est souvent diffuse et peut s'intensifier avec le mouvement ou la lumière." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de cancer ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de l'origine du cancer et de son stade." } }, { "@type": "Question", "name": "Peut-on avoir de la fièvre ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la fièvre est fréquente et peut accompagner d'autres symptômes de méningite." } }, { "@type": "Question", "name": "Peut-on prévenir la méningite carcinomateuse ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de prévention spécifique, mais un suivi régulier des cancers peut aider." } }, { "@type": "Question", "name": "Comment réduire le risque de cancer ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Adopter un mode de vie sain, éviter le tabac et l'alcool peut réduire le risque de cancer." } }, { "@type": "Question", "name": "Les vaccinations aident-elles ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccinations ne préviennent pas la méningite carcinomateuse, mais protègent d'autres types." } }, { "@type": "Question", "name": "Quel rôle joue le dépistage ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage précoce des cancers peut aider à éviter des complications comme la méningite." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains facteurs environnementaux peuvent augmenter le risque de développer un cancer." } }, { "@type": "Question", "name": "Quel est le traitement principal ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement principal inclut la chimiothérapie intrathécale pour cibler les cellules cancéreuses." } }, { "@type": "Question", "name": "Des corticostéroïdes sont-ils utilisés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les corticostéroïdes peuvent être administrés pour réduire l'inflammation." } }, { "@type": "Question", "name": "Comment gérer la douleur ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des analgésiques et des traitements symptomatiques sont utilisés pour soulager la douleur." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des essais cliniques peuvent proposer des thérapies ciblées ou immunothérapies." } }, { "@type": "Question", "name": "Quel suivi est nécessaire après traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier est essentiel pour surveiller la réponse au traitement et les récidives." } }, { "@type": "Question", "name": "Quelles sont les complications possibles ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des déficits neurologiques, des infections et des douleurs chroniques." } }, { "@type": "Question", "name": "La méningite carcinomateuse peut-elle être fatale ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être fatale si non traitée, en raison de l'aggravation des symptômes neurologiques." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent gravement affecter la qualité de vie, entraînant des limitations fonctionnelles." } }, { "@type": "Question", "name": "Y a-t-il un risque de récidive ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de récidive est élevé, surtout si le cancer primaire n'est pas contrôlé." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Quels cancers sont associés à la méningite carcinomateuse ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les cancers du poumon, du sein et les lymphomes sont souvent associés à cette condition." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque augmente avec l'âge, surtout chez les personnes ayant des antécédents de cancer." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent que les hommes peuvent être plus à risque que les femmes." } }, { "@type": "Question", "name": "Les antécédents familiaux sont-ils un facteur ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque de méningite carcinomateuse." } }, { "@type": "Question", "name": "Les traitements antérieurs augmentent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains traitements comme la radiothérapie peuvent augmenter le risque de méningite carcinomateuse." } } ] } ] }

Sources (10000 au total)

CNS Inflammation as the First Sign of Complement Factor I Deficiency.

Complement factor I (CFI) deficiency is a rare autosomal recessive inborn error of immunity. In this report, we highlight that complete CFI deficiency may present with isolated and severe CNS inflamma... This is a case description of a young girl with severe longitudinal transverse myelitis treated with aggressive immunotherapy that included eculizumab. Published cases of CFI-associated CNS inflammati... A primary immunodeficiency panel revealed 2 germline pathogenic variants in the CFI gene. Further complement testing of the index case and her family confirmed complete CFI deficiency.... We describe a unique case of severe spinal inflammation secondary to complete CFI deficiency. Although rare, isolated CNS inflammation may be the primary manifestation of complete CFI deficiency. To h...

Thrombotic microangiopathy due to acquired complement factor I deficiency in a male receiving interferon-beta treatment for multiple sclerosis.

Interferon-beta (IFNβ), the most widely prescribed medication for multiple sclerosis, is generally considered safe. Nevertheless, rare serious and/or life-threatening side effects have been reported s... We report thrombotic microangiopathy in a 28-year-old male receiving interferon-beta treatment for multiple sclerosis.... After three years of starting interferon beta therapy, the patient presented with malignant hypertension causing seizures, rapidly progressive renal failure requiring haemodialysis and haemolytic anae... IFNβ treatment may cause complement factor I deficit, which can lead to thrombotic microangiopathy and severe renal failure....

Complement factor D regulates collagen type I expression and fibroblast migration to enhance human tendon repair and healing outcomes.

Dense connective tissues (DCTs) such as tendon, ligament, and cartilage are important stabilizers and force transmitters in the musculoskeletal system. The healing processes after DCT injuries are hig... Quantitative mass spectrometry (QMS) profiling of tissue biopsies from the inflammatory phase of healing (n = 40 patients) and microdialysates from the proliferative phase of healing (n = 28 patients)... The QMS profiling of tissue biopsies from the inflammatory phase of healing identified 769 unique proteins, and microdialysates from the proliferative phase of healing identified 1423 unique proteins ... The results of the current studies characterized underlying inflammatory- and proliferative healing mechanisms by which CFD potentially improved tendon repair. These findings may lead to improved indi... http://clinicaltrials.gov, identifiers NCT02318472, NCT01317160....

An assessment of prevalence of Type 1 CFI rare variants in European AMD, and why lack of broader genetic data hinders development of new treatments and healthcare access.

Advanced age-related macular degeneration (AAMD) risk is associated with rare complement Factor I (FI) genetic variants associated with low FI protein levels (termed 'Type 1'), but it is unclear how v... Collective prevalence of Type 1 CFI rare variant genotypes were examined in four European AAMD datasets. Collective minor allele frequencies (MAFs) were sourced from the natural history study SCOPE, t... Type 1 CFI rare variants were enriched in all European AAMD cohorts, with odds ratios (ORs) ranging between 3.1 and 7.8, and a greater enrichment was observed in dry AMD from FINBB (OR 8.9, 95% CI 1.4... The relationship between Type 1 CFI rare variants increasing odds of AAMD are well established in Europeans, however the lack of broader genetic data in AAMD has adverse implications for clinical deve...